Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
Abstract
Summary In many phase I trials, the design goal is to find the dose associated with a certain target toxicity rate. In some trials, the goal can be to find the dose with a certain weighted sum of rates of various toxicity grades. For others, the goal is to find the dose with a certain mean value of a continuous response. In this article, we describe a dose‐finding design that can be used in any of the dose‐finding trials described above, trials where the target dose is defined as the dose at which a certain monotone function of the dose is a prespecified value. At each step of the proposed design, the normalized difference between the current dose and the target is computed. If that difference is close to zero, the dose is repeated. Otherwise, the dose is increased or decreased, depending on the sign of the difference.
Citing Literature
Number of times cited according to CrossRef: 26
- Pavel Mozgunov, Mauro Gasparini, Thomas Jaki, A surface-free design for phase I dual-agent combination trials, Statistical Methods in Medical Research, 10.1177/0962280220919450, (096228022091945), (2020).
- Xiang Li, Anastasia Ivanova, Hong Tian, Pilar Lim, Kevin Liu, Continual reassessment method with regularization in phase I clinical trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1818251, (1-15), (2020).
- Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui, Model-Based Designs Considering Toxicity Alone, Dose-Finding Designs for Early-Phase Cancer Clinical Trials, 10.1007/978-4-431-55585-8_3, (33-79), (2019).
- Pavel Mozgunov, Thomas Jaki, A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints, Biometrical Journal, 10.1002/bimj.201800313, 61, 6, (1477-1492), (2019).
- Monia Ezzalfani, How to design a dose-finding study on combined agents: Choice of design and development of R functions, PLOS ONE, 10.1371/journal.pone.0224940, 14, 11, (e0224940), (2019).
- M. Clertant, J. O’Quigley, Semiparametric dose finding methods: special cases, Journal of the Royal Statistical Society: Series C (Applied Statistics), 10.1111/rssc.12308, 68, 2, (271-288), (2018).
- Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui, Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui, Dose Finding for a Combination of Two Agents, Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents, 10.1007/978-4-431-55573-5_2, (9-40), (2018).
- Shing M Lee, Moreno Ursino, Ying Kuen Cheung, Sarah Zohar, Dose-finding designs for cumulative toxicities using multiple constraints, Biostatistics, 10.1093/biostatistics/kxx059, 20, 1, (17-29), (2017).
- Xuezhou Mao, Ying Kuen Cheung, Sequential designs for individualized dosing in phase I cancer clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2016.08.018, 63, (51-58), (2017).
- Anastasia Ivanova, Yunfei Wang, Matthew C. Foster, The rapid enrollment design for Phase I clinical trials, Statistics in Medicine, 10.1002/sim.6886, 35, 15, (2516-2524), (2016).
- Nolan A. Wages, Anastasia Ivanova, Olga Marchenko, Practical designs for Phase I combination studies in oncology, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2015.1092029, 26, 1, (150-166), (2015).
- Bin Cheng, Shing M. Lee, On the consistency of the continual reassessment method with multiple toxicity constraints, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2015.03.001, 164, (1-9), (2015).
- Xiaobin Yang, Keying Ye, Yanping Wang, A study of the probit model with latent variables in Phase I clinical trials, Journal of Statistical Computation and Simulation, 10.1080/00949655.2014.885976, 85, 8, (1621-1633), (2014).
- Yunfei Wang, Anastasia Ivanova, Dose finding with continuous outcome in phase I oncology trials, Pharmaceutical Statistics, 10.1002/pst.1662, 14, 2, (102-107), (2014).
- M.‐K. Riviere, F. Dubois, S. Zohar, Competing designs for drug combination in phase I dose‐finding clinical trials, Statistics in Medicine, 10.1002/sim.6094, 34, 1, (1-12), (2014).
- Anastasia Ivanova, Gary L. Rosner, Olga Marchenko, Tom Parke, Inna Perevozskaya, Yanping Wang, Advances in Statistical Approaches to Oncology Drug Development, Therapeutic Innovation & Regulatory Science, 10.1177/2168479013501309, 48, 1, (81-89), (2013).
- Suyu Liu, Chunyan Cai, Jing Ning, Up-and-down designs for phase I clinical trials, Contemporary Clinical Trials, 10.1016/j.cct.2013.07.002, 36, 1, (218-227), (2013).
- Anastasia Ivanova, Changfu Xiao, Dose finding when the target dose is on a plateau of a dose–response curve: comparison of fully sequential designs, Pharmaceutical Statistics, 10.1002/pst.1585, 12, 5, (309-314), (2013).
- Monia Ezzalfani, Sarah Zohar, Rui Qin, Sumithra J. Mandrekar, Marie‐Cécile Le Deley, Dose‐finding designs using a novel quasi‐continuous endpoint for multiple toxicities, Statistics in Medicine, 10.1002/sim.5737, 32, 16, (2728-2746), (2013).
- Changfu Xiao, Anastasia Ivanova, Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2012.01.024, 142, 7, (1899-1907), (2012).
- Takashi Daimon, The Continual Reassessment Method (CRM) and Related Topics^|^mdash;A Review. Part II: Modified/Extended CRMs and Related Designs., Japanese Journal of Biometrics, 10.5691/jjb.33.31, 33, 1, (31-76), (2012).
- D. Azriel, M. Mandel, Y. Rinott, The treatment versus experimentation dilemma in dose finding studies, Journal of Statistical Planning and Inference, 10.1016/j.jspi.2011.03.001, 141, 8, (2759-2768), (2011).
- Alexia Iasonos, Sarah Zohar, John O'Quigley, Incorporating lower grade toxicity information into dose finding designs, Clinical Trials: Journal of the Society for Clinical Trials, 10.1177/1740774511410732, 8, 4, (370-379), (2011).
- John Whitehead, Helene Thygesen, Anne Whitehead, A Bayesian dose‐finding procedure for phase I clinical trials based only on the assumption of monotonicity, Statistics in Medicine, 10.1002/sim.3963, 29, 17, (1808-1824), (2010).
- B. Nebiyou Bekele, Yisheng Li, Yuan Ji, Risk‐Group‐Specific Dose Finding Based on an Average Toxicity Score, Biometrics, 10.1111/j.1541-0420.2009.01297.x, 66, 2, (541-548), (2009).
- Sarah Zohar, John O'Quigley, Sensitivity of dose-finding studies to observation errors, Contemporary Clinical Trials, 10.1016/j.cct.2009.06.008, 30, 6, (523-530), (2009).
